Back to HALO
Livforsakringsbolaget Skandia, Omsesidigt → HALO
Livforsakringsbolaget Skandia, Omsesidigt HALO Position History
Halozyme Therapeutics, Inc. • Healthcare
Quarters held
5
Latest value
$15.4M
Q3 2026
Peak value
$15.4M
First seen
Q3 2025
Dollar value over time
Show data table
| Period | Position value |
|---|---|
| Q3 2025 | $7.7M |
| Q4 2025 | $7.1M |
| Q1 2026 | $7.5M |
| Q2 2026 | $9.7M |
| Q3 2026 | $15.4M |
Quarter-by-quarter history
Every disclosed snapshot of the position
| Quarter | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|
| Q3 2026 | $15.4M | 139.4K | — | — |
| Q2 2026 | $9.7M | 124.1K | — | — |
| Q1 2026 | $7.5M | 116.1K | — | — |
| Q4 2025 | $7.1M | 104.9K | — | — |
| Q3 2025 | $7.7M | 104.9K | — | — |
Other funds holding HALO
$545.3M
$405.4M
$405.4M
$319.1M
$251.9M
$236.6M
$176.7M
$148.6M